[
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Analysis Sets",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.1",
    "population": "SCR",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "First and Last Contact in the Study",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.2",
    "population": "SCR",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by Country - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.3.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by Country - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.3.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by Analysis Visit - Run-in",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.4.1",
    "population": "RI",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by Analysis Visit - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.4.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by Analysis Visit - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.4.3",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by 3-monthly Periods in Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.5.1",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Participant Disposition by 3-monthly Periods in Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.5.2",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Analysis Phase/Period Duration - Run-in and Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.6.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Analysis Phase/Period Duration - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.6.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Discontinuation - Screening and Run-in Period",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.1.7.1",
    "population": "SCR",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Discontinuation - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.1.7.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Discontinuation - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.1.7.3",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Treatment Discontinuation - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.1.8.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Treatment Discontinuation - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.1.8.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Protocol Deviations - Run-in and Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.9.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Protocol Deviations - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.1.9.2",
    "population": "ITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Demographic Data - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.2.1.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Demographic Data - Stage B - SAF-B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.2.1.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Demographic Data - Stage B - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.1.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Baseline Disease Characteristics - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.2.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Baseline Disease Characteristics - Stage B - SAF-B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.2.2.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Baseline Disease Characteristics - Stage B - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.2.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Medical History - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.3.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Medical History - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.3.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Concomitant Diseases - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.4.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Concomitant Diseases - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.4.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Prior Therapies by ATC Class (Level 1 and Level 3) and Generic Term - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.5.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Prior Therapies by ATC Class (Level 1 and Level 3) and Generic Term - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.5.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Number of Prior CIDP Therapies by Prior CIDP Medication at Screening - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.5.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Number of Prior CIDP Therapies by Prior CIDP Medication at Screening - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.5.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Concomitant Therapies by ATC Class (Level 1 and Level 3) and Generic Term - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.6.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Concomitant Therapies by ATC Class (Level 1 and Level 3) and Generic Term - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.6.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Drug Administration - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.2.7.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Drug Administration - Stage B - SAF-B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.1.2.7.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Drug Administration - Stage B - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.7.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Mode of Study Drug Administration - Stage B - SAF-B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.7.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Mode of Study Drug Administration - Stage B - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.7.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Table",
    "title": "Study Drug Self-Administration Training",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.2.8",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders - Exact Clopper Pearson Confidence Interval",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.1.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders by Way of Deterioration During the Run-in Phase - Frequency Tabulation",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.1.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders by Prior CIDP Medication at Screening - Frequency Tabulation and Exact Clopper Pearson Confidence Interval",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.1.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders by Analysis Visit - Frequency Tabulation",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.1.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders, Excluding Participants that Were Ongoing in Stage A at the 88th Event in Stage B - Exact Clopper Pearson Confidence Interval",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.1.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders by Prior CIDP Medication at Screening, Excluding Participants that Were Ongoing in Stage A at the 88th Event in Stage B - Exact Clopper Pearson Confidence Interval",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.1.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Confirmed ECI Responders (Based on Investigator’s Assessment) - Exact Clopper Pearson Confidence Interval",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.1.7",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to Initial Confirmed ECI - Kaplan-Meier",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to Initial Confirmed ECI by Prior CIDP Medication at Screening - Kaplan-Meier",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.2.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to Initial Confirmed ECI, Excluding Participants that Were Ongoing in Stage A at the 88th Event in Stage B - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.2.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to Initial Confirmed ECI by Prior CIDP Medication at Screening, Excluding Participants that Were Ongoing in Stage A at the 88th Event in Stage B - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.2.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to Initial Confirmed ECI (Censored at Week 12) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.2.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to Initial Confirmed ECI (Censored at Week 12) by Prior CIDP Medication at Screening - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.2.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to First Improvement - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.3.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Time to First Improvement by Prior CIDP Medication at Screening - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.3.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A specific parameters",
    "type": "Table",
    "title": "Cross-tabulation of way of ECMD Deterioration During the Run-in Phase Versus Way of Confirmed ECI During Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.4.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Primary Endpoint) - Cox Proportional Hazard Model - mITT",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.1.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline - Cox Proportional Hazard Model - PP",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.1.2",
    "population": "PP",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline - Cox Proportional Hazard Model - mITT Excluding Participants Who Did Not Have Confirmed ECI in Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.2.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Extreme-case Analysis) - Cox Proportional Hazard Model",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.2.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Mixed-Case Analysis) - Cox Proportional Hazard Model",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.2.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Based on Investigator’s Assessment) - Cox Proportional Hazard Model",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.2.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Using Actual Values of the Stratification Factors) - Cox Proportional Hazard Model",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.2.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Prior CIDP Medication - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Adjusted INCAT Score in Stage A - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Sex at Birth - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Region - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Race - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Age Group - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.6",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Body Weight (kg) - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.7",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by CIDP Disease Activity Status - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.8",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by BMI (kg/m2) - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.3.9",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline - Kaplan-Meier - mITT",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.4.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline - Kaplan-Meier - PP",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.4.2",
    "population": "PP",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline - Kaplan-Meier - mITT Excluding Participants Who Did Not Have Confirmed ECI in Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.4.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Extreme-case Analysis) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Mixed-Case Analysis) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.6",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Based on Investigator’s Assessment) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.7",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline (Using Actual Values of the Stratification Factors) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.8",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Prior CIDP Medication - Kaplan-Meier",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.9.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Adjusted INCAT Score in Stage A - Kaplan-Meier",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.9.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Sex at Birth - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Region - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Race - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Age Group - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.6",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Body Weight (kg) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.7",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by CIDP Disease Activity Status - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.8",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by BMI (kg/m2) - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.5.9.9",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Relapse (Adjusted INCAT Clinical Deterioration) Rate",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.5.10",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to CIDP Disease Progression - Cox Proportional Hazard Model",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.6.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to CIDP Disease Progression by Prior CIDP Medication - Cox Proportional Hazard Model",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.6.2.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to CIDP Disease Progression by Adjusted INCAT Score in Stage A - Cox Proportional Hazard Model",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.6.2.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to CIDP Disease Progression - Kaplan-Meier",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.6.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to CIDP Disease Progression by Prior CIDP Medication - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.6.4.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to CIDP Disease Progression by Adjusted INCAT Score in Stage A - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.6.4.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Improved Functional Level - Logistic Regression",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.7.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Improved Functional Level by Prior CIDP Medication - Logistic Regression",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.7.2.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Improved Functional Level by Adjusted INCAT Score in Stage A - Logistic Regression",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.7.2.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage B specific parameters",
    "type": "Table",
    "title": "Time to 10% Decrease in I-RODS - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.8.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.9.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Confirmed ECI Response - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.9.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Prior CIDP Medication - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.2.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by ECMD Worsening on Adjusted INCAT - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.2.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline at Stage A Baseline and Last Assessment by Prior CIDP Medication and by ECMD Worsening on Adjusted INCAT - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.2.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Treatment Duration Group in Stage A - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.9.2.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Prior CIDP Medication - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.4.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Adjusted INCAT Score in Stage A - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.4.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline at Last Assessment and at Best-Improvement - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline at Last Assessment and at Best-Improvement by Prior CIDP Medication - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.6.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline at Last Assessment and at Best-Improvement by Adjusted INCAT Score in Stage A - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.6.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.9.7",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline by Prior CIDP Medication - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.8.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline by Adjusted INCAT Score in Stage A - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.8.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline by Treatment Duration Group in Stage B - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.9.8.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline at Last Assessment - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.9",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline at Last Assessment by Prior CIDP Medication - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.10.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage B Baseline at Last Assessment by Adjusted INCAT Score in Stage A - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.10.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Adjusted INCAT Disability Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.9.11",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.10.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Confirmed ECI Response - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.10.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Prior CIDP Medication - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.10.2.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline ECMD Worsening on Adjusted INCAT - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.10.2.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by ECMD Worsening on I-RODS - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.10.2.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline at Stage A Baseline and Last Assessment by Prior CIDP Medication and by ECMD Worsening on I-RODS - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.10.2.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Treatment Duration Group in Stage A - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.10.2.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.10.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline at Last Assessment - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.10.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline by Treatment Duration Group in Stage B - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.10.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "I-RODS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.10.6",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.11.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Confirmed ECI Response - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.11.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Prior CIDP Medication - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.11.2.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline by ECMD Worsening on Adjusted INCAT - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.11.2.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline by ECMD Worsening on Mean Grip Strength - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.11.2.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline at Stage A Baseline and Last Assessment by Prior CIDP Medication and by ECMD Worsening on Mean Grip Strength - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.11.2.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline by Treatment Duration Group in Stage A - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.11.2.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.11.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline at Last Assessment - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.11.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline by Treatment Duration Group in Stage B - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.2.11.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Mean Grip Strength (kPa): Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.11.6",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Total MRC Sum Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.12.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Total MRC Sum Score: Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.12.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Total MRC Sum Score: Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline at Last Assessment - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.12.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Total MRC Sum Score: Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.12.4",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Time to Complete TUG Test (Sec): Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.13.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Time to Complete TUG Test (Sec): Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.13.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Time to Complete TUG Test (Sec): Descriptive Statistics of Actual Values, Changes from Stage A Baseline and Changes from Stage B Baseline at Last Assessment - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.13.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Stage A, Stage B, Stage A+B parameters",
    "type": "Table",
    "title": "Time to Complete TUG Test (Sec): Descriptive Statistics of Actual Values and Changes from Stage A Baseline - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.13.4",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Exposure and Total IgG Quartiles Analysis",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Quartile of CTroughSS  - Kaplan-Meier - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.14.1",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Exposure and Total IgG Quartiles Analysis",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Quartile of AUCss  - Kaplan-Meier - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.14.2",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/Exposure and Total IgG Quartiles Analysis",
    "type": "Table",
    "title": "Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Quartile of AUECss - Kaplan-Meier - mITT",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.14.3",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/PHARMACOKINETICS",
    "type": "Table",
    "title": "Descriptive Statistics of Efgartigimod Serum Concentration (µg/mL) over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.15.1",
    "population": "PK-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/PHARMACOKINETICS",
    "type": "Table",
    "title": "Descriptive Statistics of Efgartigimod Serum Concentration (µg/mL) over Time for Japanese Participants - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.15.2",
    "population": "PK-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/PHARMACOKINETICS",
    "type": "Table",
    "title": "Descriptive Statistics of Efgartigimod Serum Concentration (µg/mL) over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.15.3",
    "population": "PK-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/PHARMACODYNAMICS",
    "type": "Table",
    "title": "Descriptive Statistics of Total IgG Actual Values, Changes and Percent Changes from Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.16.1",
    "population": "PD-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/PHARMACODYNAMICS",
    "type": "Table",
    "title": "Descriptive Statistics of Total IgG Actual Values, Changes and Percent Changes from Stage A Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.16.2",
    "population": "PD-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Anti-Drug Antibodies Against Efgartigimod Sample Classification by Analysis Visit by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.1",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Anti-Drug Antibodies Against Efgartigimod Sample Classification by Analysis Visit by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.2",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Anti-Drug Antibodies Against Efgartigimod Participant Classification, Prevalence and Incidence - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.3",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Anti-Drug Antibodies Against Efgartigimod Participant Classification, Prevalence and Incidence by Prior CIDP Medication at Screening - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.4",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Anti-Drug Antibodies Against Efgartigimod Participant Classification, Prevalence and Incidence - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.5",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Anti-Drug Antibodies Against Efgartigimod Participant Classification, Prevalence and Incidence - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.6",
    "population": "IMM-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Descriptive Statistics of ADA Against Efgartigimod Titer Values by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.7",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "ADA: Descriptive Statistics of ADA Against Efgartigimod Titer Values by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.8",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: rHuPH20 Antibodies Sample Classification by Analysis Visit by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.9",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: rHuPH20 Antibodies Sample Classification by Analysis Visit by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.10",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: rHuPH20 Antibodies Participant Classification, Prevalence and Incidence - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.11",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: rHuPH20 Antibodies Participant Classification, Prevalence and Incidence by Prior CIDP Medication at Screening - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.12",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: rHuPH20 Antibodies Participant Classification, Prevalence and Incidence - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.13",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: rHuPH20 Antibodies Participant Classification, Prevalence and Incidence - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.14",
    "population": "IMM-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: Descriptive Statistics of rHuPH20 Antibody Titer Values by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.15",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: Descriptive Statistics of rHuPH20 Antibody Titer Values by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.16",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: Number and Percentage of rHuPH20 Antibody Positive Participants by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.17",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "rHuPH20 Antibody: Number and Percentage of rHuPH20 Antibody Positive Participants by Anti-Drug Antibodies Participant Against Efgartigimod Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.18",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Neutralizing Antibodies Against Efgartigimod Sample Classification by Analysis Visit by Nab Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.19",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Neutralizing Antibodies Against Efgartigimod Sample Classification by Analysis Visit by Nab Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.20",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Neutralizing Antibodies Against Efgartigimod Participant Classification,  Prevalence and Incidence - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.21",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Neutralizing Antibodies Against Efgartigimod Participant Classification, Prevalence and Incidence - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.22",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Neutralizing Antibodies Against Efgartigimod Participant Classification, Prevalence and Incidence - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.23",
    "population": "IMM-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Number and Percentage of NAb Against Efgartigimod Positive Participants by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.24",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against Efgartigimod: Number and Percentage of NAb Against Efgartigimod Positive Participants by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.25",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against rHuPH20: Neutralizing Antibodies Against rHuPH20 Sample Classification by Analysis Visit by rHuPH20 Nab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.26",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against rHuPH20: Neutralizing Antibodies Against rHuPH20 Sample Classification by Analysis Visit by rHuPH20 Nab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.27",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against rHuPH20: Neutralizing Antibodies Against rHuPH20 Participant Classification, Prevalence and Incidence - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.28",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against rHuPH20: Neutralizing Antibodies Against rHuPH20 Participant Classification, Prevalence and Incidence - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.29",
    "population": "IMM-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "NAb Against rHuPH20: Neutralizing Antibodies Against rHuPH20 Participant Classification, Prevalence and Incidence - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.17.30",
    "population": "IMM-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "Efficacy Correlation: Confirmed ECI Responders by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Frequency Tabulation",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "Efficacy Correlation: Confirmed ECI Responders by NAb Against Efgartigimod Participant Classification - Frequency Tabulation",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "Efficacy Correlation: Confirmed ECI Responders by rHuPH20 Ab Participant Classification - Frequency Tabulation",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "Efficacy Correlation: Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "Efficacy Correlation: Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by NAb Against Efgartigimod Participant Classification - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.5",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "Efficacy Correlation: Time to Adjusted INCAT Deterioration Compared to Stage B Baseline by rHuPH20 Ab Participant Classification - Kaplan-Meier",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.6",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PK Correlation: Mean Efgartigimod Serum Concentration (µg/mL) over Time by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.7",
    "population": "PK-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PK Correlation: Mean Efgartigimod Serum Concentration (µg/mL) over Time by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.8",
    "population": "PK-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PK Correlation: Mean Efgartigimod Serum Concentration (µg/mL) over Time by NAb Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.9",
    "population": "PK-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PK Correlation: Mean Efgartigimod Serum Concentration (µg/mL) over Time by NAb Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.10",
    "population": "PK-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PK Correlation: Mean Efgartigimod Serum Concentration (µg/mL) over Time by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.11",
    "population": "PK-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PK Correlation: Mean Efgartigimod Serum Concentration (µg/mL) over Time by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.12",
    "population": "PK-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PD Correlation: Mean Total IgG Percent Changes from Stage A Baseline by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.13",
    "population": "PD-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PD Correlation: Mean Total IgG Percent Changes from Stage A Baseline by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.14",
    "population": "PD-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PD Correlation: Mean Total IgG Percent Changes from Stage A Baseline by NAb Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.15",
    "population": "PD-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PD Correlation: Mean Total IgG Percent Changes from Stage A Baseline by NAb Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.16",
    "population": "PD-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PD Correlation: Mean Total IgG Percent Changes from Stage A Baseline by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.17",
    "population": "PD-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "PD Correlation: Mean Total IgG Percent Changes from Stage A Baseline by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.18",
    "population": "PD-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.19",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.20",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by NAb Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.21",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by NAb Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.22",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.23",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.24",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.25",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.26",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by NAb Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.27",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by NAb Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.28",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.29",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.30",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection-Related Reactions by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.31",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection-Related Reactions by Anti-Drug Against Efgartigimod Antibodies Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.32",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation Treatment-Emergent Injection-Related Reactions by NAb Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.33",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection-Related Reactions by NAb Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.34",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection-Related Reactions by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.35",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection-Related Reactions by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.36",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection Site Reactions by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.37",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection Site Reactions by Anti-Drug Antibodies Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.38",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation Treatment-Emergent Injection Site Reactions by NAb Against Efgartigimod Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.39",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection Site Reactions by NAb Against Efgartigimod Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.40",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection Site Reactions by rHuPH20 Ab Participant Classification - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.41",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/IMMUNOGENICITY",
    "type": "Table",
    "title": "AE Correlation: Treatment-Emergent Injection Site Reactions by rHuPH20 Ab Participant Classification - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.18.42",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "EQ-5D-5L: Tabulation of  the 5 Dimensions over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.19.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "EQ-5D-5L: Tabulation of the 5 Dimensions over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.19.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "EQ-5D-5L: Descriptive Statistics of Actual Values and Changes from Stage A Baseline in VAS Score over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.20.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "EQ-5D-5L: Descriptive Statistics of Actual Values and Changes from Stage B Baseline in VAS Score over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.20.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "BPI-SF: Tabulation of Pain Other than Everyday Kinds over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.21.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "BPI-SF: Tabulation of Pain Other than Everyday Kinds over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.21.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "BPI-SF: Descriptive Statistics of Actual Values and Changes from Stage A Baseline over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.22.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "BPI-SF: Descriptive Statistics of Actual Values and Changes from Stage B Baseline over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.22.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "TSQM-9: Descriptive Statistics of Actual Values by Prior CIDP Medication at Run-in - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.23.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "TSQM-9: Descriptive Statistics of Actual Values by Prior CIDP Medication at Run-in - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.23.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "TSQM-9: Descriptive Statistics of Actual Values over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.23.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "TSQM-9: Descriptive Statistics of Actual Values over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.23.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "RT-FSS: Tabulation of  the Individual Items over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.24.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "RT-FSS: Tabulation of  the Individual Items over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.24.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "RT-FSS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.25.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "RT-FSS: Descriptive Statistics of Actual Values and Changes from Stage B Baseline over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.25.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "HADS: Tabulation of  the Individual Items over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.26.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "HADS: Tabulation of  the Individual Items over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.26.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "HADS: Descriptive Statistics of Actual Values and Changes from Stage A Baseline of the Total Scores over Time- Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.27.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "HADS: Descriptive Statistics of Actual Values and Changes from Stage B Baseline of the Total Scores over Time - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.27.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "HADS: Tabulation of Depression and Anxiety Score > 8 - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.28.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "HADS: Tabulation of Depression and Anxiety Score > 8 - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.28.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "PGIC: Tabulation of PGIC Outcome over Time - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.29.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Table",
    "title": "PGIC: Tabulation of PGIC Outcome over Time- Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.2.29.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview - Stage A + B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.3",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.5",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A + B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.6",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.7",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.8",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Non-serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.9",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Non-serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.10",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Grade 3 or More Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.11",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Grade 3 or More Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.12",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.13",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.14",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Procedure-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.15",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Procedure-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.16",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.17",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.18",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events Leading to Interruption of Study Drug by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.19",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events Leading to Interruption of Study Drug by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.20",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events of Special Interest by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.21",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events of Special Interest by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.22",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events of Special Interest by MedDRA System Organ Class, Preferred Term and Worst Severity - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.23",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Adverse Events of Special Interest by MedDRA System Organ Class, Preferred Term and Worst Severity - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.24",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Injection-Related Reactions by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.25",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Injection-Related Reactions by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.26",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Serious Treatment-Emergent Injection-Related Reactions by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.27",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Serious Treatment-Emergent Injection-Related Reactions by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.28",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Injection Site Reactions Overview - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.29",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Injection Site Reactions Overview - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.30",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Injection Site Reactions Overview by 3-monthly Periods - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.31",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Injection Site Reactions Overview by 3-monthly Periods - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.32",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Injection Site Reactions by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.33",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Injection Site Reactions by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.1.34",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Injection Site Reactions by MedDRA System Organ Class and Preferred Term by 3-monthly Periods - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.35",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Treatment-Emergent Injection Site Reactions by MedDRA System Organ Class and Preferred Term by 3-monthly Periods - Stage A+B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.36",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Serious Treatment-Emergent Injection Site Reactions by MedDRA System Organ Class and Preferred Term - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.37",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Serious Treatment-Emergent Injection Site Reactions by MedDRA System Organ Class and Preferred Term - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.1.3.38",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Time to First Onset and Duration of Treatment-Emergent Adverse Events of Special Interest - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.39",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Time to First Onset and Duration of Treatment-Emergent Adverse Events of Special Interest - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.40",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "COVID-19 Events Overview - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.41",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "COVID-19 Events Overview - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.42",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview by Quartile of AUCss - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.43.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview by Quartile of AUCss - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.43.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview by Quartile of AUECss Stage A - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.43.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Table",
    "title": "Adverse Events Overview by Quartile of AUECss Stage B - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.1.43.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Table",
    "title": "Descriptive Statistics of Laboratory Test Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Table",
    "title": "Descriptive Statistics of Laboratory Test Actual Values and Changes from Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.2.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Table",
    "title": "Cross-Tabulation of Laboratory Abnormalities Versus Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.2.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Table",
    "title": "Cross-Tabulation of Laboratory Abnormalities Versus Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.2.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Table",
    "title": "Cross-Tabulation of Laboratory Toxicity Grades Versus Stage A Baseline - Stage A",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.2.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Table",
    "title": "Cross-Tabulation of Laboratory Toxicity Grades Versus Stage B Baseline - Stage B",
    "Col_A": "TLR",
    "Col_B": "",
    "num": "14.3.2.6",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/VITAL SIGNS",
    "type": "Table",
    "title": "Descriptive Statistics of Vital Signs Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.3.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/VITAL SIGNS",
    "type": "Table",
    "title": "Descriptive Statistics of Vital Signs Actual Values and Changes from Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.3.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/VITAL SIGNS",
    "type": "Table",
    "title": "Cross-Tabulation of Vital Signs Abnormalities Versus Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.3.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/VITAL SIGNS",
    "type": "Table",
    "title": "Cross-Tabulation of Vital Signs Abnormalities Versus Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.3.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Table",
    "title": "Descriptive Statistics of ECG Actual Values and Changes from Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.4.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Table",
    "title": "Descriptive Statistics of ECG Actual Values and Changes from Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.4.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Table",
    "title": "Cross-Tabulation of ECG Abnormalities Versus Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.4.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Table",
    "title": "Cross-Tabulation of ECG Abnormalities Versus Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.4.4",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Table",
    "title": "Tabulation of QTc Change Abnormalities Compared to Stage A Baseline - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.4.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Table",
    "title": "Tabulation of QTc Change Abnormalities Compared to Stage B Baseline - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.4.6",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/SUICIDALITY",
    "type": "Table",
    "title": "Suicidality Assessment - Stage A",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.5.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/SUICIDALITY",
    "type": "Table",
    "title": "Suicidality Assessment - Stage B",
    "Col_A": "",
    "Col_B": "",
    "num": "14.3.5.2",
    "population": "SAF-B",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Analysis Sets",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.1.1",
    "population": "SCR",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Treatment Allocation",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.1.2",
    "population": "ITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Analysis Phases and Periods",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.1.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Study and Treatment Discontinuation",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.1.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Protocol Deviations",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.2.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Violations on Eligibility Criteria",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.2.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "CIDP Confirmation Committee",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.2.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "No-Treatment Participants",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.2.4",
    "population": "SCR minus SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Demographic Data",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.4.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Baseline Disease Characteristics",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.4.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Screening Tests and Suicidality",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.4.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Medical History and Concomitant Diseases",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.4.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Prior and Concomitant Therapies",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.4.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Prior and Concomitant Procedures",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.4.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Study Drug Administration",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.5.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "GENERAL CHARACTERISTICS/",
    "type": "Listing",
    "title": "Self-Administration Training",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.5.2",
    "population": "SAF-AB",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PHARMACOKINETICS/",
    "type": "Listing",
    "title": "Individual Efgartigimod Serum Concentrations and Relative Time to Last Dosing",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.5.3",
    "population": "PK-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "ECI",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "First Improvement",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "INCAT Disability Score",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "Adjusted INCAT Deterioration",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.4",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "I-RODS",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "CIDP Disease Progression, Improved Functional Level and 10% Decrease in I-RODS",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.6",
    "population": "mITT",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "Mean Grip Strength",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.7",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "MRC Sum Score",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.8",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "EFFICACY/",
    "type": "Listing",
    "title": "TUG Test",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.9",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PHARMACODYNAMICS/",
    "type": "Listing",
    "title": "Total IgG",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.10",
    "population": "PD-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "IMMUNOGENICITY/",
    "type": "Listing",
    "title": "Anti-Drug Antibodies and Neutralizing Antibodies Against Efgartigimod",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.11",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "IMMUNOGENICITY/",
    "type": "Listing",
    "title": "Antibodies and Neutralizing Antibodies Against rHuPH20",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.12",
    "population": "IMM-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Listing",
    "title": "EQ-5D-5L",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.13",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Listing",
    "title": "BPI-SF",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.14",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Listing",
    "title": "TSQM-9",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.15",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Listing",
    "title": "RT-FSS",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.16",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Listing",
    "title": "HADS",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.17",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "PATIENT REPORTED OUTCOMES/",
    "type": "Listing",
    "title": "PGIC",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.6.18",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Adverse Events",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Run-in Adverse Events",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.2",
    "population": "SCR",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Serious Adverse Events",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Fatal Adverse Events",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Adverse Events of Special Interest",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "COVID-19 Events",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.7",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ADVERSE EVENTS",
    "type": "Listing",
    "title": "Adverse Events: Coding Information",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.7.8",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Listing",
    "title": "Laboratory Test Results for Participants with Abnormal Values",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.8.1",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/LABORATORY DATA",
    "type": "Listing",
    "title": "Urinalysis and Lipid Laboratory Test Results",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.8.2",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/VITAL SIGNS",
    "type": "Listing",
    "title": "Vital Signs Results for Participants with Abnormal Values",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.8.3",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/ECG",
    "type": "Listing",
    "title": "ECG Results for Participants with Abnormal Values",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.8.4",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/PE",
    "type": "Listing",
    "title": "Physical Examination Results for Participants with Abnormal Values",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.8.5",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  },
  {
    "section": "SAFETY/SUICIDALITY",
    "type": "Listing",
    "title": "Suicidality Assessments for Participants with Abnormal Values",
    "Col_A": "",
    "Col_B": "",
    "num": "16.2.8.6",
    "population": "SAF-A",
    "program": "",
    "params": "",
    "assigned": "",
    "comments": ""
  }
]
